L & S Advisors Inc Bluebird Bio, Inc. Transaction History

L & S Advisors Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 13, 2020	SELL	$46.96 - $61.67 $385,118 - $505,755	-8,201 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$59.47 - $93.1 $4,519 - $7,075	76 Added 0.94%	8,201 $753,000
Q2 2019 Aug 13, 2019	BUY	$75.84 - $105.21 $33,142 - $45,976	437 Added 5.68%	8,125 $1.03 Million
Q1 2019 May 14, 2019	BUY	$64.44 - $104.11 $202,019 - $326,384	3,135 Added 68.86%	7,688 $1.21 Million
Q4 2018 Feb 14, 2019	SELL	$59.1 - $93.26 $134,275 - $211,886	-2,272 Reduced 33.29%	4,553 $452,000
Q3 2018 Nov 14, 2018	SELL	$88.86 - $117.49 $347,176 - $459,033	-3,907 Reduced 36.41%	6,825 $996,000
Q2 2018 Aug 13, 2018	BUY	$99.64 - $127.59 $603,220 - $772,429	6,054 Added 129.41%	10,732 $1.68 Million
Q1 2018 May 14, 2018	BUY	$105.8 - $150.94 $23,064 - $32,904	218 Added 4.89%	4,678 $799,000
Q4 2017 Feb 14, 2018	BUY	$81.25 - $130.7 $362,375 - $582,922	4,460	4,460 $794,000

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $28.5M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of L & S Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on L & S Advisors Inc with notifications on news.